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Background: Adaptive aerosol delivery (AAD) nebuliser devices can reduce treatment times whilst enabling adherence to be monitored using
inbuilt data logs. Using one such device, we have monitored nebulised antibiotic adherence in children with Cystic Fibrosis (CF).
Methods: In CF children infected with Pseudomonas aeruginosa, downloaded data from an AAD device was used to calculate morning, evening
and overall monthly adherence to antibiotic therapy over a year.
Results: Overall monthly adherence to nebulised antibiotic therapy in 28 children was maintained between 60 and 70% over the year. Considerable
variation in adherence, both between and within patients, was evident (Mean [SD] coefficient of variation, 37[44]%). Evening adherence (75[37]%)was
better than morning adherence (58[34]%: p=0.012). Treatment regimens were changed in 8/28 patients based on adherence data.
Conclusions: Routine adherence monitoring can be implemented in an outpatient setting. Using this type of information it is possible to identify
which aspects of treatment can be improved and to work together with families to individualise treatments.
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The World Health Organisation has defined adherence as
“the extent to which a person's behaviour-taking medication,
following a diet and/or executing lifestyle changes, corresponds
with agreed recommendations from a health care provider” [1].
It is increasingly being recognised that managing and promoting
adherence is an essential component of care in chronic disease,
where adherence to advice or medical treatment is often less
than 50% [2]. There are no perfect “gold standard” methods for☆ Some of these data has been presented in the form of a poster at the
European Cystic Fibrosis Conference in June 2007 in Belek, Turkey.
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doi:10.1016/j.jcf.2009.04.006measuring adherence however electronic monitoring devices
are considered the most valid [3,4].
In Cystic Fibrosis (CF), rates of adherence vary depending on
the type of treatment and the method of measurement [5]. Thus
pancreatic enzyme adherence in children with CF is much higher
when assessed by parent self-report (89.5%) than by more
objective means such as electronic pillboxes or pharmacy refill
data (42.5% and 46.4% respectively) [5]. Adherence to nebulised
dornase alpha monitored using empty returned vials ranges from
54% in adults to 78% in children and adolescents [6,7]. Only 30%
of adults with CF undertake daily chest physiotherapy [8]. These
studies highlight the considerable potential for optimising
treatment in patients with CF by improving rates of adherence.
The recent development of small, handheld portable
nebulisers, which utilise mesh technology for aerosol produc-
tion and delivery has enabled much faster treatment times for
CF patients [9,10]. Some of these ‘adaptive aerosol delivery’d by Elsevier B.V. All rights reserved.
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monitoring when the device is used, for how long and whether a
full dose is taken. When combined with knowledge of the
patient's prescribed treatment regime, these data can be used to
calculate adherence. In an effort to reduce treatment burden by
decreasing treatment times and based on recommendations from
our local Drugs and Therapeutics committee, one such AAD
device (I-neb™, Respironics, Chichester, UK) was introduced
into our CF clinic in March 2005. In contrast to standard
nebulisers which deliver a constant flow of aerosol, the I-neb
only releases medication during inspiration, providing a more
efficient delivery of drug to the lungs. Since its introduction,
adherence data have been routinely downloaded, monitored and
shared with patients/parents in the clinic and used to inform
clinical decision making if appropriate.
To determine how adherent our young patients were to their
nebulised antibiotic therapies, this study retrospectively exam-
ined adherence to inhaled antibiotic treatment through the I-neb
over the first 12 months of its usage in a paediatric CF
population chronically infected with Pseudomonas aeruginosa
(PsA).
2. Methods
2.1. Study design
In this observational study, data analysed and collected
retrospectively from routine clinical practice were examined
with the primary outcome measure being adherence (number of
recorded doses/number of prescribed doses ×100) and a
secondary outcome measure being treatment time (minutes).
2.2. Participants
Participants were 2–15 years of age and attended the
regional paediatric CF clinic at Alder Hey Children's Hospital
(n=106). Inclusion criteria for the study comprised all patients
with pulmonary PsA infection who trialled a new AAD device
(I-neb™, Respironics, Chichester, UK) and in whom the first
12 months adherence data from the start of its usage was available.
Patient demographics and clinical characteristics including themost
recent sputum/cough swab microbiology and annual review results
(pulmonary function tests, Northern Chest X-ray Score, and
Schwachman score) prior to starting the I-neb were recorded.
2.3. Device, drug delivery and monitoring
A commercial preparation of colistin was used (Promixin®,
Profile Pharma Ltd., Chichester, UK) with a standard treatment
dose being 1 MU (mega unit) diluted in 2 ml normal saline (1 ml
being used for each of two daily treatments). In some patients, a
once daily “double strength dose” was prescribed which
involved diluting 1 MU Promixin® in 1 ml normal saline.
The I-neb AAD systemmonitors and analyses the patient's first
three breaths to determine inspiratory and expiratory flow patterns
and then pulses aerosol during the mid-phase of the next
inspiration. The device calculates the volume of each inhalationand once the pre-programmed dose is delivered, gives audio and
visual feedback informing the patient that treatment is complete.
Families were made aware of the data logging facility within the
device and were told that this information would be downloaded
and discussed routinely with them in clinic. Patients and their
parents were encouraged to bring their handheld I-neb device to all
clinic appointments. At clinic, onemember of the CF team (PMcC)
accessed the data log via a reading cradle using dedicated computer
software provided by the manufacturer with the I-neb (‘Insight
system’, Respironics, Chichester, UK). Modifications to treatment
regimens, such as changing inhaled antibiotic from twice-daily to
once-daily, were made based on downloaded adherence data.
The Insight software package includes a training screen and
breathing monitor programme. When first given the new device,
patients were trained to use slow, deep, controlled inhalations.
Breathing technique was subsequently assessed each time the
patient attended clinic and feedback given as appropriate. Data
download and technique assessment took 5–10 min per patient.
2.4. Measurements
Data were downloaded each time patients/parents brought
their devices into clinic. The device has sufficient memory to
record 5000 events allowing adherence to be calculated
retrospectively if clinic appointments were missed or the device
was forgotten. Duration of treatment time was analysed monthly
following start of therapy. The number and time of day
treatments were taken were compared to the number of
treatments prescribed, allowing morning (treatment taken
betweenmidnight andmidday), evening (treatment taken between
midday and midnight) and overall adherence to be calculated.
Adherencewas defined as the number of taken treatments/number
of prescribed treatments ×100%.
2.5. Statistics
Morning, evening and overall adherence over the first six
months of treatment were used as summary measures. Patient
adherence data were normally distributed when analysedmonthly
and so were expressed as mean [standard deviation] with
differences examined using a paired samples t test. Variability
in adherence both within and between patients was investigated
statistically using the coefficient of variation. Data were displayed
graphically as mean [standard error of the mean (SEM)] or as line
graphs. Where data were non-parametric or for the purposes of
clarity, they were also expressed as median [range].
All statistical tests were two tailed and a p value equal to or
less than 0.05, taken as statistically significant. Statistical
calculations were performed using SPSS 15.0 statistical
package (SPSS Inc., Chicago, USA).
2.6. Ethics
Clarification regarding the nature of the study was sought from
the local Research, Development and Ethics Users Views Group.
Following a review of the methodology, the opinion of this
committee was that this study constituted service evaluation. All
Fig. 1. Mean (SEM) time for medication to be taken through the I-neb over the
twelve months following start of treatment. Mean [SD] treatment time increased
over the year from 3.8[2.1] minutes (median [range], 3[2–11] minutes) during
the first month of treatment to 5.9[4.2] minutes (4[1–20] minutes) during the
twelfth month (p=0.002).
Fig. 2. Morning and evening adherence in children (n=28) for the six months
following start of treatment. Evening adherence was significantly higher than
that in the morning (p=0.012). The obvious outlier is a teenager who, on
schooldays, took both his daily treatments immediately after school and towards
midnight, rather than in the morning.
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treatment was being monitored routinely.
3. Results
3.1. Participants
FromMarch 2005, 48 patients infected with chronic and new
growths of P. aeruginosa were given the opportunity to trial the
I-neb.
35% (17/48) patients had chronic pulmonary PsA infection
and were already prescribed nebulised colistin through
conventional nebulisers when they changed to the I-neb. Five
of these 17 patients were also prescribed nebulised dornase
alpha through the I-neb. As it was not possible to differentiate
adherence to individual nebulised therapies from data down-
loaded from the I-neb, data from these patients was analysed
separately. 2/17 patients subsequently reverted to their previous
nebulisers because of parental/adolescent preference.
65% (31/48) had new growths of PsA identified on
respiratory culture and were prescribed three months nebulised
colistin through the I-neb and three weeks of oral ciprofloxacin
according to CF trust guidelines [11]. 20 of these 31 patients
were not clear of PsA on respiratory culture following 3 months
treatment and so continued on nebulised colistin for twelve
months in accordance with the local protocol. Two of these
patients were also prescribed nebulised dornase alpha through
the I-neb and so their data was analysed separately with those
patients on dornase alpha and chronically infected with PsA.
Overall, twelvemonths data on adherence to nebulised colistin
in 28 patients (10 chronically PsA infected and 18 new PsA
growths; 16/28 male; median [range] age, 9.1 [2.8–14.9] years)
was available for analysis. Annual review data prior to starting the
I-neb revealed a median [range] FEV1 of 75 [54–99]%, a
Northern Chest X-ray Score of 4.0 [2.9] and a combinedSchwachman score of 85[60–100]. PsA was cultured from
sputum or cough swab from all children, with isolates from 12/28
being consistently positive for the Liverpool Epidemic Strain.
Children with chronic PsA infection (n=10) already prescribed
nebulised colistin through conventional nebulisers were demo-
graphically and clinically similar to those children with persistent
new growths (n=18) ofPsA apart from having higher chest X-ray
scores (Chronic PsA, 5.8(3.2); Persistent new PsA, 3.0(2.2);
p=0.011).
Adherence data were routinely made available to clinicians
in clinic. On the basis of poor adherence to inhaled therapy, 8/28
patients had their treatment regime changed from twice daily to
a once daily double-dose of colistin during the second six
months of the year.3.2. Duration of treatment
16,102 treatment events were recorded and analysed. The
median [range] percentage of treatments which were success-
fully completed was 99[88–100]%. Fig. 1 shows the duration of
treatment in minutes plotted monthly following the start of
therapy through the I-neb. Mean [SD] treatment time increased
over the year from 3.8[2.1] minutes (median [range], 3[2–11]
minutes) during the first month of treatment to 5.9[4.2] minutes
(4[1–20] min) during the twelfth month (p=0.002).3.3. Adherence
Mean [SD] overall adherence over the first six months of
treatment through the I-neb was 67[31]% with 12/28 patients
Fig. 4. Monthly overall adherence for individual patients over the first year of
treatment. Considerable variation is seen both between and within patients.
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significantly better in the evenings (75[37]%) than in the
mornings(58[34]%: p=0.012) (Fig. 2). Considerable variation
in adherence between patients was seen but evening adherence
was at least 10% greater than morning adherence in 12/28
patients. When adherence was analysed as a group at monthly
intervals (data not shown), mean evening adherence was
consistently at least 10% greater than that in the morning.
There was a tendency for overall adherence to be better in
children less than twelve years of age (71[31]%) than in
teenagers (50[26]%) but teenager numbers were small (n=6).
Adherence over the first six months in those children taking
both nebulised colistin and dornase alpha, was similar to those
children just taking nebulised colistin (dornase alpha+colistin,
67[35]%; colistin, 64[35]%: p=0.85).
Overall mean and median monthly adherence from a group
perspective was maintained over the year between 60 and 70%
(Fig. 3), albeit by changing treatment regimens in some patients
in the second six months of the year. However, considerable
variation in adherence both between individuals and within
individuals was apparent (Mean [SD] coefficient of variation,
37[44]%) (Fig. 4). A variety of adherence patterns and
behaviours were seen. Some patients took their medication
more often than prescribed whilst others didn't take any. Some
started well and then adherence decreased, or started poorly and
then adherence improved.
In those eight patients in whom treatment was changed from
twice daily to once daily in the second half of the year because
of poor adherence, mean [SD] adherence in the month pre- and
post-change increased significantly from 26%[22] to 54%[32]Fig. 3. Mean (SEM) overall adherence for the year following start of treatment.
All patients were prescribed twice daily colistin for the first six months of
treatment. During the second six months of the year, eight patients were changed
to once daily double-dose colistin based on their adherence data.respectively(p=0.011) (Fig. 5). In some this level of adherence
was maintained but in others it fell to previous levels and by the
third month following change in treatment regime, there was no
statistically significant difference in overall adherence (38%
[37], p=0.66).Fig. 5. Adherence to treatment in the three months before and after a change in
treatment regime from twice daily to once daily double-dose colistin. A transient
improvement in adherence is demonstrated in most patients.
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This is the first study to examine the use of routine open
adherence monitoring over a prolonged period of time in an
outpatient setting. Overall, we have shown that monthly adherence
to nebulised therapies in a group of CF children infected with PsA
is maintained with support at between 60 and 70%. We have
demonstrated considerable variation both between and particularly
within patients, and that adherence to inhaled therapy in this group
of children is better in the evenings than in the mornings. We have
also shown that treatment times for medication through the I-neb
gradually increases over time. Finally we have shown that it is
possible to incorporate routine monitoring of adherence in the
outpatient setting.
The use of routine adherence monitoring in an un-selected
cohort of patients with a particular condition outside a trial
scenario is unusual. In conditions such as asthma, epilepsy and
some rheumatological conditions, drug levels are sometimes
monitored as part of routine clinical practice but this is more
often to avoid toxicity than to check adherence. In many
diseases, pharmacy refill data is reviewed, sometimes covertly,
where adherence is of concern in individual patients but we are
not aware of this being undertaken routinely in whole clinics.
Attempts at assessing and improving adherence in selected
patients to treatments in an HIV or TB setting using electronic
pillboxes have also been described [12,13]. Most of these
studies involve either isolated measurements or short-term
assessments of adherence. The strength of this study was the
duration of follow-up, which has enabled us to identify trends in
adherence over time and an increase in treatment times.
Overall monthly adherence rates over the year in our cohort
of CF patients were between 60 and 70%, similar to quoted rates
from short-term randomised controlled trials of dornase alpha
(66–71%) based on pharmacy refill data [5,7]. Perceived
wisdom maintains that adherence to treatment generally
decreases with the duration and complexity of treatment [2].
In contrast, adherence was maintained in our cohort, probably
for a number of reasons. Firstly, adherence data was discussed
with families at every clinic visit stressing the importance these
inhaled therapies were to the CF team. Secondly, changing the
treatment regimes in those patients who were struggling with a
twice daily regimen made a difference to adherence at least in
the short-term. Importantly, these data can be used to inform a
power calculation to study the role of regular routine adherence
monitoring and treatment re-enforcement on overall adherence
to treatment.
Whilst variation in adherence in chronic disease between
patients is well-known and documented, the degree to which
adherence varies within individual patients has to our knowl-
edge not been adequately described before. The coefficient of
variation data and particularly Fig. 4 clearly, if rather
chaotically, illustrates both these types of variation within our
cohort. The discussion of each patient's adherence data in clinic
following download provides the opportunity to openly ask
why adherence might have slipped or why treatment times have
increased. Some of the variation in adherence probably relates
to short-term improvements just prior or post outpatient clinicappointments. However, families are often very willing to offer
other explanations for sub-optimal adherence. For example, a
drop in evening adherence in one patient was readily explained
by the start of a major televised football tournament. Qualitative
studies are required to determine the behaviours that impact on
adherence and help to identify families at risk of poor adherence
so that strategies can be initiated to support them.
A potential problemwith assessing adherence in chronic disease
is that treatment regimens may change [5]. In our cohort, regimes
for eight patients were changed in the second six months of the
study on the basis of poor adherence to treatment. Although there
was a significant improvement in adherence in the first month
following change, this effect tended to be short-lived. However,
although colistin was administered only once daily, its dose was
doubled and so the amount of colistin taken daily actually increased
in five of the eight patients studied. The information derived by
routine adherence monitoring allows for treatment regimes to be
tailored to individual circumstances and behaviours. In some of
these children, these data prompted discussions as to different
treatment strategies or whether treatment should be discontinued.
The finding that evening adherence in our cohort of children
was significantly better than morning adherence is also novel.
Adult studies on adherence to antihypertensive medications and
paediatric studies on immunosuppressive therapy in acute
lymphoblastic leukaemia show the opposite, i.e. that morning is
generally better than evening adherence [14–16]. However, in
asthma, adult adherence to inhaled corticosteroids is better in the
evenings than in the mornings [17], and similarly, adherence to
inhaled corticosteroids in children measured indirectly by counting
the remaining doses in an inhaler device, was consistently 6–9%
better in the evenings than the mornings [18]. The relatively large
difference (N10%) we observed may reflect a combination of the
time-consuming nature of nebulised treatment with the hectic
morning schedules described by many of our families.
Treatment times increased over the year from a mean of
3.8 min during the first month of treatment to 5.9 min by month
twelve. Reasons for this may have included practical issues with
the device such as ineffective or infrequent cleaning resulting in
drug deposition on the mesh plate. Mesh plates were routinely
replaced after six months use or sooner if a problem was
identified. Other potential reasons for increased treatment times
were patient issues, with the novelty of the device wearing off
over the year and the child becoming more distractable, with a
consequent worsening of breathing technique
This study has a number of limitations. Firstly, as a service
evaluation we have not been able to compare adherence using
different nebulisers or measurement methods. However, con-
ventional nebulisers for the most part do not allow direct
measurement of adherence and it is questionable how useful
comparing direct and indirect methods of measurements of
adherence would be. Another limitation was that it was
generally not possible to calculate adherence to individual
treatments such as colistin and dornase alpha, in those patients
taking more than one medication through the I-neb.
In summary, this study has evaluated the current practice in
our clinic where adherence to inhaled treatment is routinely
monitored and results discussed openly with parents/patients.
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how families accommodate this into daily life. As a result, we
have been able to identify which aspects of treatment can be
improved and have worked together with families to indivi-
dualise treatment regimes. Our results suggest that this type of
interaction can result in sustainable levels of adherence over
twelve months. However a randomised controlled trial is
required to confirm this.
As new technologies develop in many areas of medicine, it is
important that health professionals give consideration to issues
of monitoring adherence. What this study demonstrates is the
potential that such devices provide for health professionals to
work in an open partnership with patients and their families.
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